SCIENTURE Announces Third Patent Grant for ARBLI(TM) (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041

Stock Information for Wellgistics Health Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Wellgistics Health Inc.

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY(TM) (naloxone hydrochloride) to Wholesalers
SCIENTURE Expands Arbli(TM) Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
SCIENTURE Secures Formulary Coverage for REZENOPY(TM) with a Large National Health Plan and Expands Commercial Team
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
SCIENTURE Receives U.S. Patent Covering REZENOPY(TM) (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.